Developer docs
API playgroundTry for free, no card

Search company profiles

Seraphina Therapeutics

Full company profile

uuid0000blk

Namestring
Seraphina Therapeutics
Legal namestring
Seraphina Therapeutics, Inc.
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Seraphina Therapeutics is a San Diego-based, privately held health and wellness company founded in 2017 (commercial launch January 2021) by husband-and-wife team Dr. Stephanie Venn-Watson (DVM, MPH, veterinary epidemiologist) and Dr. Eric Venn-Watson (MD, MBA, former Navy physician), together with co-founders Kim Kamdar (Managing Partner at Domain Associates, board chair) and Nicholas Schork (Senior Scientist; Distinguished Professor at Translational Genomics Institute / City of Hope). The company commercializes C15:0 (pentadecanoic acid), an odd-chain saturated fatty acid it characterizes as the first essential fatty acid discovered in over 90 years. The underlying IP originated in Dr. Venn-Watson's 20+ years of U.S. Navy research on bottlenose dolphins in San Diego; Seraphina holds exclusive global licensing rights from the U.S. Navy (U.S. Patent No. 11,116,740) for C15:0 as a supplement, food/beverage ingredient, and pharmaceutical, alongside 60+ granted and pending patents across metabolic, heart, liver, immune, brain, and healthy-aging indications.

The company's commercial product line is sold under the fatty15 brand: the original C15:0 dietary supplement distributed via a direct-to-consumer e-commerce subscription model (fatty15.com), and the practitioner-exclusive Fatty15 Advanced Formula Extra Strength launched in June 2026 through Fullscript, a platform serving 125,000+ healthcare practitioners and 5 million+ patients annually across North America. The D2C subscription business has scaled to 100,000+ active subscribers with a 95% monthly retention rate since launch, and the brand has earned 30+ industry awards (including the 2025 CNBC Changemaker for the CEO, Inc. 5000 fastest-growing supplement company in 2025, and multiple 2026 GHP, Mindful, and Beauty Shortlist accolades). The firm is backed by a single disclosed $5.5 million funding round (May 2020) led by Domain Associates with Murano Group, indicating a capital-efficient operating model. Scientific positioning is supported by 150+ peer-reviewed publications and a meta-analysis linking higher circulating C15:0 to a 32% lower risk of type 2 diabetes, with scientific advisors including Edward Dennis (UC San Diego) and Ronald Krauss (Harvard). The company has no disclosed AI/ML capabilities and its competitive advantage rests on patent exclusivity, clinical evidence, and founder credibility rather than data or machine-learning assets.

Short descriptiontext

Seraphina Therapeutics is a San Diego-based health company that commercializes C15:0 (pentadecanoic acid) — the first essential fatty acid discovered in over 90 years — under its fatty15 brand, selling C15:0 supplements direct-to-consumer and through healthcare practitioners via Fullscript.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
dietary supplements, essential fatty acids, nutritional supplements, longevity supplements, cellular health nutrition
Industry2 codes
PRIMARYCRADAGAM
Healthy Aging & Cognitive Support Supplements
SECONDARYCRADAGAE
Specialty Condition Supplements (Sleep, Stress, Heart, Joint, Gut, Immunity)
NAICS code1 code
  • Food (Health) Supplement Retailers456191
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Dietary Supplements
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1C15:0 Supplement Sales (Direct-to-Consumer)
TypeSubscription Recurring
Description

Seraphina Therapeutics generates revenue through direct-to-consumer sales of its fatty15 C15:0 supplement brand via e-commerce. The company has built a subscription-based model with over 100,000 active subscribers and a 95% monthly retention rate since January 2021 launch.

prnewswire.com
2Practitioner-Exclusive Supplement Sales
TypeSubscription Recurring
Description

Revenue from selling the higher-dose Fatty15 Advanced Formula Extra Strength exclusively to healthcare practitioners through the Fullscript platform, serving over 125,000 practitioners and 5 million patients annually.

prnewswire.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1fatty15
Description

Primary C15:0 supplement brand launched in January 2021, offering essential fatty acid supplements for healthy aging. Includes original formula and Advanced Formula Extra Strength for practitioners.

prnewswire.com
Core offering1 text field

Seraphina Therapeutics develops and sells C15:0 (pentadecanoic acid) dietary supplements under the fatty15 brand for healthy aging and cellular health. Its core consumer product, the fatty15 C15:0 supplement, is sold via subscription through the company's direct-to-consumer e-commerce site, while a higher-dose practitioner-exclusive variant, Fatty15 Advanced Formula Extra Strength, is distributed exclusively through the Fullscript platform to healthcare practitioners who recommend it to patients. Both products are backed by 150+ peer-reviewed studies and an exclusive global licensing arrangement for C15:0 from the U.S. Navy and the United States of America.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 32% lower risk of type 2 diabetes per 0.1% increase in C15:0 levels (meta-analysis in Advances in Nutrition)
+3 more records
Product overview1 text field

Seraphina Therapeutics is a health and wellness company that developed C15:0 (pentadecanoic acid) supplements based on research initially conducted studying U.S. Navy dolphins. The company offers two products: Fatty15, the core consumer supplement brand and the first essential fatty acid supplement in over 90 years; and Fatty15 Advanced Formula Extra Strength, a higher-dose practitioner-exclusive variant distributed through the Fullscript platform. Both products are backed by peer-reviewed research supporting healthy aging benefits.

Product and service2 records
1Fatty15 C15:0 Supplement
CategoryDietary Supplements
Description

The flagship fatty15 C15:0 (pentadecanoic acid) dietary supplement sold directly to consumers via the fatty15.com e-commerce platform on a subscription basis, supporting cellular health, metabolic health, and healthy aging. Over 100,000 active subscribers with a 95% monthly retention rate since launch.

2Fatty15 Advanced Formula Extra Strength
CategoryDietary Supplements
Description

A higher-dose practitioner-exclusive C15:0 supplement available exclusively through the Fullscript platform for healthcare practitioners (doctors, naturopaths, health coaches) to recommend to their patients for metabolic, liver, cardiovascular, and inflammatory conditions.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-05
Description

Seraphina Therapeutics partnered with Fullscript to make Fatty15 Advanced Formula Extra Strength available exclusively to healthcare practitioners. Fullscript is a platform trusted by over 125,000 healthcare practitioners serving more than 5 million patients annually across North America with supplements and clinical care tools.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct peer: science-backed DTC longevity supplement brand built around a single proprietary molecule (NAD+ precursor, Basis) with strong IP and clinical credibility. Closest 1:1 analog to Seraphina's C15:0 / fatty15 model.

TypeDirect peer
Description

Science-driven supplement brand selling practitioner-grade and DTC products across multiple categories including healthy aging and metabolic health. Comparable subscription-based DTC model with practitioner channel.

3AG1 (Athletic Greens)
TypeDirect peer
Description

Iconic DTC supplement subscription brand with very high retention and lifestyle positioning. Comparable growth trajectory, subscription model, and consumer health messaging.

TypeDirect peer
Description

Premium DTC supplement brand with subscription model, science-forward branding, and category-spanning product line. Similar brand positioning and consumer demographics to fatty15.

TypeDirect peer
Description

Practitioner-exclusive supplement brand with broad product portfolio including metabolic, cardiovascular, and liver support formulations. Comparable to Fatty15's Fullscript practitioner channel play.

TypeDirect peer
Description

Long-established science-based supplement brand with strong longevity and cardiometabolic positioning. Comparable consumer demographic and direct-to-consumer supplement portfolio.

TypeDirect peer
Description

NutriDyn/Pure Encapsulations is a practitioner-grade supplement brand with strong metabolic and cardiovascular health positioning. Overlaps directly with Fatty15 Advanced Formula's practitioner channel.

TypeEmerging player
Description

Emerging premium supplement brand with science-first positioning and longevity-adjacent products. Compares on brand narrative and DTC execution, though smaller practitioner footprint.

TypeBroad incumbent
Description

Broad incumbent in medical nutrition, supplements, and longevity nutrition. Relevant as a potential acquirer or partner, and as a scaled competitor with deeper distribution into pharmacy and clinical channels.

TypeEmerging player
Description

Microbiome-focused DTC supplement brand with a subscription model and science-forward branding. Comparable consumer demographic and DTC mechanics, though differentiated category focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Seraphina Therapeutics

Dietary Supplementsseraphinatherapeutics.com

Seraphina Therapeutics is a San Diego-based health company that commercializes C15:0 (pentadecanoic acid) — the first essential fatty acid discovered in over 90 years — under its fatty15 brand, selling C15:0 supplements direct-to-consumer and through healthcare practitioners via Fullscript.

What Seraphina Therapeutics does

Seraphina Therapeutics is a San Diego-based, privately held health and wellness company founded in 2017 (commercial launch January 2021) by husband-and-wife team Dr. Stephanie Venn-Watson (DVM, MPH, veterinary epidemiologist) and Dr. Eric Venn-Watson (MD, MBA, former Navy physician), together with co-founders Kim Kamdar (Managing Partner at Domain Associates, board chair) and Nicholas Schork (Senior Scientist; Distinguished Professor at Translational Genomics Institute / City of Hope). The company commercializes C15:0 (pentadecanoic acid), an odd-chain saturated fatty acid it characterizes as the first essential fatty acid discovered in over 90 years. The underlying IP originated in Dr. Venn-Watson's 20+ years of U.S. Navy research on bottlenose dolphins in San Diego; Seraphina holds exclusive global licensing rights from the U.S. Navy (U.S. Patent No. 11,116,740) for C15:0 as a supplement, food/beverage ingredient, and pharmaceutical, alongside 60+ granted and pending patents across metabolic, heart, liver, immune, brain, and healthy-aging indications.

The company's commercial product line is sold under the fatty15 brand: the original C15:0 dietary supplement distributed via a direct-to-consumer e-commerce subscription model (fatty15.com), and the practitioner-exclusive Fatty15 Advanced Formula Extra Strength launched in June 2026 through Fullscript, a platform serving 125,000+ healthcare practitioners and 5 million+ patients annually across North America. The D2C subscription business has scaled to 100,000+ active subscribers with a 95% monthly retention rate since launch, and the brand has earned 30+ industry awards (including the 2025 CNBC Changemaker for the CEO, Inc. 5000 fastest-growing supplement company in 2025, and multiple 2026 GHP, Mindful, and Beauty Shortlist accolades). The firm is backed by a single disclosed $5.5 million funding round (May 2020) led by Domain Associates with Murano Group, indicating a capital-efficient operating model. Scientific positioning is supported by 150+ peer-reviewed publications and a meta-analysis linking higher circulating C15:0 to a 32% lower risk of type 2 diabetes, with scientific advisors including Edward Dennis (UC San Diego) and Ronald Krauss (Harvard). The company has no disclosed AI/ML capabilities and its competitive advantage rests on patent exclusivity, clinical evidence, and founder credibility rather than data or machine-learning assets.

Seraphina Therapeutics firmographics

Firmographics
Name
Seraphina Therapeutics
Legal name
Seraphina Therapeutics, Inc.
Website
https://seraphinatherapeutics.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Seraphina Therapeutics is a San Diego-based health company that commercializes C15:0 (pentadecanoic acid) — the first essential fatty acid discovered in over 90 years — under its fatty15 brand, selling C15:0 supplements direct-to-consumer and through healthcare practitioners via Fullscript.
Ownership category
akta.pro rank

Seraphina Therapeutics industry classification

Industry
Product category
Dietary Supplements
NAICS
Food (Health) Supplement Retailers (456191)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYCRADAGAM
Healthy Aging & Cognitive Support Supplements
SECONDARYCRADAGAE
Specialty Condition Supplements (Sleep, Stress, Heart, Joint, Gut, Immunity)

Keywords

  • Dietary supplements
  • Essential fatty acids
  • Nutritional supplements
  • Longevity supplements
  • Cellular health nutrition

Where Seraphina Therapeutics is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Markets served

Seraphina Therapeutics business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations

Revenue model

  1. C15:0 Supplement Sales (Direct-to-Consumer): Seraphina Therapeutics generates revenue through direct-to-consumer sales of its fatty15 C15:0 supplement brand via e-commerce. The company has built a subscription-based model with over 100,000 active subscribers and a 95% monthly retention rate since January 2021 launch.
  2. Practitioner-Exclusive Supplement Sales: Revenue from selling the higher-dose Fatty15 Advanced Formula Extra Strength exclusively to healthcare practitioners through the Fullscript platform, serving over 125,000 practitioners and 5 million patients annually.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Seraphina Therapeutics product offering

Product offering

Core offering

Seraphina Therapeutics develops and sells C15:0 (pentadecanoic acid) dietary supplements under the fatty15 brand for healthy aging and cellular health. Its core consumer product, the fatty15 C15:0 supplement, is sold via subscription through the company's direct-to-consumer e-commerce site, while a higher-dose practitioner-exclusive variant, Fatty15 Advanced Formula Extra Strength, is distributed exclusively through the Fullscript platform to healthcare practitioners who recommend it to patients. Both products are backed by 150+ peer-reviewed studies and an exclusive global licensing arrangement for C15:0 from the U.S. Navy and the United States of America.

Product overview

Seraphina Therapeutics is a health and wellness company that developed C15:0 (pentadecanoic acid) supplements based on research initially conducted studying U.S. Navy dolphins. The company offers two products: Fatty15, the core consumer supplement brand and the first essential fatty acid supplement in over 90 years; and Fatty15 Advanced Formula Extra Strength, a higher-dose practitioner-exclusive variant distributed through the Fullscript platform. Both products are backed by peer-reviewed research supporting healthy aging benefits.

Differentiator

Problem solved

Functional benefit

Brands

  • fatty15: Primary C15:0 supplement brand launched in January 2021, offering essential fatty acid supplements for healthy aging. Includes original formula and Advanced Formula Extra Strength for practitioners.

Products and services

  • Fatty15 C15:0 Supplement The flagship fatty15 C15:0 (pentadecanoic acid) dietary supplement sold directly to consumers via the fatty15.com e-commerce platform on a subscription basis, supporting cellular health, metabolic health, and healthy aging. Over 100,000 active subscribers with a 95% monthly retention rate since launch.
  • Fatty15 Advanced Formula Extra Strength A higher-dose practitioner-exclusive C15:0 supplement available exclusively through the Fullscript platform for healthcare practitioners (doctors, naturopaths, health coaches) to recommend to their patients for metabolic, liver, cardiovascular, and inflammatory conditions.

Quantifiable outcome

  • 32% lower risk of type 2 diabetes per 0.1% increase in C15:0 levels (meta-analysis in Advances in Nutrition)
  • +3 more outcomes

Companies that use Seraphina Therapeutics

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Seraphina Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Seraphina Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • FullscriptcoreChannel Partner/ Reseller/ Distributor · 5 June 2026Seraphina Therapeutics partnered with Fullscript to make Fatty15 Advanced Formula Extra Strength available exclusively to healthcare practitioners. Fullscript is a platform trusted by over 125,000 healthcare practitioners serving more than 5 million patients annually across North America with supplements and clinical care tools.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Seraphina Therapeutics competitors and assessment

Company assessment

Direct peers

  • Elysium Health: Direct peer: science-backed DTC longevity supplement brand built around a single proprietary molecule (NAD+ precursor, Basis) with strong IP and clinical credibility. Closest 1:1 analog to Seraphina's C15:0 / fatty15 model.
  • Thorne HealthTech: Science-driven supplement brand selling practitioner-grade and DTC products across multiple categories including healthy aging and metabolic health. Comparable subscription-based DTC model with practitioner channel.
  • AG1 (Athletic Greens): Iconic DTC supplement subscription brand with very high retention and lifestyle positioning. Comparable growth trajectory, subscription model, and consumer health messaging.
  • Ritual: Premium DTC supplement brand with subscription model, science-forward branding, and category-spanning product line. Similar brand positioning and consumer demographics to fatty15.
  • Designs for Health: Practitioner-exclusive supplement brand with broad product portfolio including metabolic, cardiovascular, and liver support formulations. Comparable to Fatty15's Fullscript practitioner channel play.
  • Life Extension: Long-established science-based supplement brand with strong longevity and cardiometabolic positioning. Comparable consumer demographic and direct-to-consumer supplement portfolio.
  • Pure Encapsulations: NutriDyn/Pure Encapsulations is a practitioner-grade supplement brand with strong metabolic and cardiovascular health positioning. Overlaps directly with Fatty15 Advanced Formula's practitioner channel.

Emerging players

  • Momentous: Emerging premium supplement brand with science-first positioning and longevity-adjacent products. Compares on brand narrative and DTC execution, though smaller practitioner footprint.
  • Seed Health: Microbiome-focused DTC supplement brand with a subscription model and science-forward branding. Comparable consumer demographic and DTC mechanics, though differentiated category focus.

Broad incumbents

  • Nestlé Health Science: Broad incumbent in medical nutrition, supplements, and longevity nutrition. Relevant as a potential acquirer or partner, and as a scaled competitor with deeper distribution into pharmacy and clinical channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Seraphina Therapeutics social profiles

Digital presence

Seraphina Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Seraphina Therapeutics leadership team

Management profile

Number of profiles

Profiles6 records

Seraphina Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Seraphina Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Seraphina Therapeutics

What does Seraphina Therapeutics do?

Seraphina Therapeutics develops and sells C15:0 (pentadecanoic acid) dietary supplements under the fatty15 brand for healthy aging and cellular health. Its core consumer product, the fatty15 C15:0 supplement, is sold via subscription through the company's direct-to-consumer e-commerce site, while a higher-dose practitioner-exclusive variant, Fatty15 Advanced Formula Extra Strength, is distributed exclusively through the Fullscript platform to healthcare practitioners who recommend it to patients. Both products are backed by 150+ peer-reviewed studies and an exclusive global licensing arrangement for C15:0 from the U.S. Navy and the United States of America.

Is Seraphina Therapeutics a public or private company?

Seraphina Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Seraphina Therapeutics founded?

Seraphina Therapeutics was founded in 2021. It employs 11 to 50 people.

Where is Seraphina Therapeutics based?

Seraphina Therapeutics is headquartered in San Diego, United States, in the North America region.

How does Seraphina Therapeutics make money?

Two revenue lines are on record. C15:0 Supplement Sales (Direct-to-Consumer) is the primary driver. The others are practitioner-Exclusive Supplement Sales.

Who are Seraphina Therapeutics's main competitors?

Direct peers on record are Elysium Health, Thorne HealthTech, AG1 (Athletic Greens), Ritual, Designs for Health, Life Extension and Pure Encapsulations. Emerging players are Momentous and Seed Health. Nestlé Health Science is listed as a broad incumbent.

Does Seraphina Therapeutics have an API?

No public API is recorded for Seraphina Therapeutics.

What industry is Seraphina Therapeutics in?

Seraphina Therapeutics's product category is Dietary Supplements. Its primary akta.pro industry code is CRADAGAM, Healthy Aging & Cognitive Support Supplements, with a secondary code of CRADAGAE, Specialty Condition Supplements (Sleep, Stress, Heart, Joint, Gut, Immunity). Its NAICS code is 456191 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Nutritional OutlookInc. names Seraphina Therapeutics among the top fastest-growing private consumer product companiesSeraphina Therapeutics was ranked fifth among the fastest-growing private consumer product companies in the US by Inc. magazine on August 12, 2025. The company develops fatty acid supplements and nutritional interventions, including its C15:0 supplement marketed as fatty15.Nutritional OutlookSeraphina Therapeutics partners with Genova Diagnostics to introduce at-home test that measures levels of pentadecanoic acidSeraphina Therapeutics has partnered with Genova Diagnostics to launch the Fatty15 C15:0 Test, an at-home diagnostic for measuring pentadecanoic acid levels linked to Cellular Fragility Syndrome. The test enables consumers to assess their nutritional status and potentially adjust diets or use Seraphina's fatty15 supplements to address deficiencies.Nutritional OutlookNutritional Outlook’s 2021 Best of the Industry Awards, Ingredient Supplier: Seraphina TherapeuticsSeraphina Therapeutics received the 2021 Ingredient Supplier award from Nutritional Outlook for its commercialization of pentadecanoic acid (C15:0) as the ingredient FA15 and consumer product Fatty15. The company has secured Generally Recognized as Safe (GRAS) status for FA15, enabling its use in food and beverage fortification, while reporting strong consumer retention rates for its direct-to-consumer supplement brand. Backed by research involving Navy dolphins and funded by the Department of Defense, Seraphina is expanding its pipeline to investigate other molecules with potential health benefits.New HopeNavy dolphin research unlocks C15 healthy aging boomSeraphina Therapeutics is capitalizing on the discovery of C15, an ingredient derived from Navy dolphin research, to drive growth in its Fatty15 supplement brand. The company reports a 95% user retention rate and plans to expand C15 into multi-brand formulations globally. This strategy aims to establish C15 as a widely accessible ingredient across various health products.PR NewswireFatty15 Wins Best Cellular Health Supplement Brand 2026 -- USAFatty15, a C15:0 supplement, won Best Cellular Health Supplement Brand 2026 from Global Health & Pharma. The company reports 70% of customers felt benefits within 16 weeks and a 95% monthly retention rate. It also earned TESTED by SuppCo Certification with a 9.88 TrustScore.GlobeNewswireCellular Health Screening Market Size to Reach USD 10.65 Billion by 2035 | SNS InsiderThe cellular health screening market was valued at USD 3.89 billion in 2025 and is projected to reach USD 10.65 billion by 2035, a CAGR of 10.60%. Blood tests held the largest sample-type share at 48%, while single-test panels led with 81% of test-type share. North America accounted for 47% of global revenue in 2025.PR NewswireFatty15 Earns Four Prestigious Industry Awards, Cementing Its Position as a Leading Supplement BrandSeraphina Therapeutics, Inc. announced that its fatty15 supplement brand has received four major industry awards in 2026: the Mindful Award for Wellness Company of the Year, the Beauty Shortlist 15th Anniversary Award for Wellbeing Winner, and two GHP awards for Best Essential Fatty Acid Supplement Brand and Customer Satisfaction Excellence. The recognitions highlight the brand's 95% monthly customer retention rate sustained since its January 2021 launch, more than 100,000 active subscribers, and its position as the first essential fatty acid supplement to emerge in over 90 years. The company states these awards reflect a decade of research and its commitment to delivering C15:0, an emerging foundational nutrient backed by 150 or more peer-reviewed studies, to support healthy aging.PR NewswireSeraphina Therapeutics Named the Fastest-Growing Health and Wellness Company in the Pacific in 2026 by Inc.Seraphina Therapeutics has been named the fastest-growing Health and Wellness company in the Pacific region, ranking No. 11 on Inc.'s Regionals: Pacific list of fastest-growing privately held companies covering California, Oregon, Washington, Hawaii, and Alaska. The company's fatty15 C15:0 supplement has driven strong customer retention, achieving a 95% monthly retention rate since its January 2021 launch. The recognition extends Seraphina's portfolio of industry accolades, including being named America's fastest-growing supplement company in the Inc. 5000 2025 rankings.PR NewswireFatty15 Passes the Toughest Test in SupplementsFatty15, a C15:0 supplement brand developed by Seraphina Therapeutics, has passed certification by TESTED by SuppCo, an independent testing program that verifies supplement quality by purchasing products anonymously and testing them at ISO 17025 accredited labs. The product met or exceeded 95% of tested label claims, with fatty15 agreeing to make results public regardless of outcome. The company, which has 100K+ active subscribers, 60+ patents, and 30+ awards, positions this certification as validation of its science-based approach to healthy aging supplements.CNBCStephanie Venn-Watson: 2025 CNBC ChangemakerStephanie Venn-Watson, co-founder and CEO of Seraphina Therapeutics, has been named a 2025 CNBC Changemaker for her discovery of C15:0, the first essential fatty acid identified in over 90 years. Her research began while studying U.S. Navy bottlenose dolphins in San Diego, where she found that dolphins eating fish higher in C15:0 showed better health outcomes, leading to the development of her company's supplement Fatty15. The discovery has potential implications for understanding rising rates of type 2 diabetes, heart disease, and fatty liver disease in younger populations.